Overactive Urinary Bladder (Overactive Bladder)

Subscribe to Selected New Research on Overactive Urinary Bladder

640 relevant articles (112 outcomes, 133 trials/studies) found for this Disease

Description: Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.

Also Known As:

Overactive Bladder; Urinary Bladder, Overactive; Bladder, Overactive; Overactive Detrusor Function; Detrusor Function, Overactive; Detrusor, Overactive; Overactive Detrusor

Relationship Network

Disease Context: Research Results

Male Urogenital Diseases

Urologic Diseases: 379

Urinary Bladder Diseases: 74

Overactive Urinary Bladder: 640

Female Urogenital Diseases and Pregnancy Complications

Female Urogenital Diseases

Urologic Diseases: 379

Urinary Bladder Diseases: 74

Overactive Urinary Bladder: 640

Signs and Symptoms Pathological Conditions

Signs and Symptoms

Urological Manifestations: 4

Overactive Urinary Bladder: 640

Related Diseases

1.	Syndrome
2.	Urinary Incontinence
3.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
4.	Urge Urinary Incontinence (Urge Incontinence)
5.	Nocturia
61 Diseases and 205 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Guan, Zhonghong: 10 articles (11/2008 - 04/2006)
2.	Cardozo, Linda: 9 articles (09/2008 - 12/2002)
3.	Dmochowski, Roger: 9 articles (09/2007 - 01/2005)
4.	Rovner, Eric S: 8 articles (09/2008 - 01/2002)
5.	Chancellor, Michael B: 8 articles (05/2008 - 03/2002)
6.	Abrams, Paul: 7 articles (11/2007 - 05/2005)
7.	Yamada, Shizuo: 6 articles (06/2008 - 11/2004)
8.	Dmochowski, Roger R: 6 articles (06/2007 - 06/2003)
9.	Sand, Peter K: 6 articles (02/2007 - 06/2003)
10.	Cardozo, L: 6 articles (01/2007 - 11/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Overactive Urinary Bladder:

1.	tolterodine (Detrol)FDA Link 06/01/2006 - "We evaluated the efficacy of tolterodine extended release (ER) for patients' most bothersome overactive bladder (OAB) symptom in a primary care setting" 01/01/2004 - "Based on the low frequency of adverse events, the absence of unexpected adverse events and the very low frequency of serious adverse events, we conclude that tolterodine is a well tolerated treatment for overactive bladder in adults, in whom it should be considered as first-line therapy." 04/01/2001 - "There was an improvement in voiding diary variables in all treatment groups after 2 weeks of treatment, although the efficacy was greatest in those taking 1 mg and 2 mg. Pharmacokinetic findings were consistent with dose linearity over the range 0.5-2 mg. CONCLUSION: The results support the use of 1 mg twice daily as the optimal dose of tolterodine for treating children aged 5-10 years with an overactive bladder." 05/01/2005 - "CONCLUSIONS: Favorable safety, tolerability and efficacy of once-daily tolterodine ER was maintained over 12 months in a Japanese overactive bladder patient population." 02/01/2003 - "A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder." Get all the results and reference details, order at left...
2.	oxybutynin (Tavor)FDA LinkGeneric 01/01/2002 - "While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly dry mouth" 03/01/1995 - "In summary, oxybutynin is one of the few drugs proven to be beneficial in some patients with overactive detrusor function" 12/01/2003 - "Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride" 10/20/2005 - "Of these derivatives, (+)-(1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydrochloride (9b) exhibited almost the same inhibitory activity against bladder contraction to that of oxybutynin (1), and more than 10-fold selectivity for bladder contraction versus salivary secretion, demonstrating that 9b may be useful for the treatment of symptoms associated with overactive bladder without having side effects such as dry mouth." 01/01/2000 - "Intravesical oxybutynin chloride has been reported to be effective for overactive bladder, although sometimes the efficacy does not last long enough" Get all the results and reference details, order at left...
3.	quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)IBA 11/01/2004 - "CONCLUSIONS: In this study treatment with solifenacin 5 mg and 10 mg once daily significantly improved all the major symptoms of overactive bladder including frequency, urgency and incontinence" 04/01/2004 - "At a once-daily oral dose of 5 mg/day, clinical data have shown solifenacin to be effective in reducing the symptoms of overactive bladder, with an incidence of dry mouth comparable to that associated with placebo" 11/01/2004 - "PURPOSE: In this phase 3 trial we assessed the efficacy of solifenacin 5 mg and 10 mg daily in patients with symptoms related to overactive bladder" 01/01/2006 - "Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis." 01/01/2005 - "Improved quality of life in patients with overactive bladder symptoms treated with solifenacin." Get all the results and reference details, order at left...
4.	Muscarinic AntagonistsIBA 08/01/2005 - "Antimuscarinic agents, effective in relieving symptoms of overactive bladder, are associated with anticholinergic-mediated adverse events, particularly at high dosages" 01/01/2006 - "Although effective in many cases of idiopathic and neurogenic detrusor overactivity and overactive bladder, antimuscarinic agents fall short in many other cases because of lack of efficacy and/or tolerability" 02/01/2007 - "PATIENTS AND METHODS: Urgency UI is a symptom of overactive bladder (OAB) and antimuscarinic agents are a first-line treatment for OAB symptoms; several studies have used dryness rate as an efficacy endpoint, calculated as the percentage of patients who record no UI episodes in a diary period" 12/01/2006 - "STUDY OBJECTIVE: To compare the cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB)" 03/01/2006 - "Recent studies on voiding dysfunction have clarified the association between BPH and overactive bladder (OAB), underlining the use of OAB treatment in the management of BPH, inducing the simultaneous administration of antimuscarinic agents" Get all the results and reference details, order at left...
5.	Cholinergic Antagonists (Anticholinergics)IBA 09/01/2005 - "There is a lack of study on efficacy of apha-1 blocker administration combined with anticholinergics available in our hands for patients with BPH and overactive bladder" 07/01/2006 - "Behavioural therapy and anticholinergics are the mainstays in the treatment of symptoms of overactive bladder in patients with idiopathic and neurogenic detrusor overactivity; they are the first-line treatment" 12/01/2003 - "Overactive bladder: improving the efficacy of anticholinergics by dose escalation." 01/01/1984 - "A long-term study of the effect of anticholinergics on overactive detrusor function." 05/01/2007 - "Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential." Get all the results and reference details, order at left...
6.	Botulinum Toxins (Botulinum Toxin)IBA 01/01/2007 - "Botulinum toxin B is not an effective treatment of refractory overactive bladder." 01/01/2006 - "Injections of botulinum toxin A into the detrusor muscle are a promising treatment strategy in cases of therapy-resistant overactive bladder." 01/01/2006 - "Botulinum toxin is not yet approved by the US Food and Drug Administration for the treatment of detrusor overactivity and overactive bladder, but the positive results seen thus far cannot be ignored." 12/01/2008 - "PURPOSE: We determined the efficacy of intravesical botulinum toxin A injection for refractory overactive bladder in elderly patients" 12/01/2008 - "Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population." Get all the results and reference details, order at left...
7.	darifenacin FDA Link 11/01/2006 - "OBJECTIVE: To examine, in a 2-year, non-comparative, open-label extension study, the safety, tolerability and efficacy of darifenacin controlled-release (CR) 7.5/15 mg once daily in patients with overactive bladder (OAB) who completed two 12-week randomized, double-blind, placebo-controlled 'feeder' studies" 05/01/2000 - "The results of ongoing clinical studies with darifenacin are awaited before it can be concluded that selective antagonism of M(3) receptors leads to improved tolerability over existing agents in the treatment of overactive bladder" 04/01/2008 - "A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder." 11/01/2007 - "OBJECTIVES: This analysis evaluated the long-term safety, tolerability and efficacy of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder (OAB) in patients > or = 65 years of age" 09/01/2007 - "These results may explain that the efficacy of darifenacin in overactive bladder symptoms is partly due to bladder afferent desensitization." Get all the results and reference details, order at left...
8.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 10/01/2007 - "Muscarinic receptor antagonists are effective for treatment of the overactive bladder" 03/01/2006 - "Muscarinic receptor antagonists have been reported to be effective in the treatment of overactive bladder" 05/01/2000 - "A wealth of clinical evidence supports the view that muscarinic receptor antagonists are effective in the treatment of overactive bladder" 01/01/2004 - "INTRODUCTION: Antimuscarinic drugs have frequently been used for the treatment for patients with an overactive bladder (OAB) and there have been many studies on the distribution of muscarinic receptor subtypes in the bladder" 04/01/2008 - "OBJECTIVE: To investigate the primary pharmacology of fesoterodine (a novel antimuscarinic drug developed for treating overactive bladder) and SPM 7605 (its active metabolite, considered to be the main pharmacologically active principle of fesoterodine in man) against human muscarinic receptor subtypes, and to investigate in vitro and in vivo functional activity of these agents on the rat bladder compared with existing standard agents" Get all the results and reference details, order at left...
9.	Capsaicin (Zostrix)IBA 05/01/2002 - "On the other hand, capsaicin has not been shown to be clearly effective in treatment of overactive bladder caused by detrusor overactivity or suprapontine pathology without the emergent C-fiber-mediated reflex" 09/01/2003 - "The efficacy of Thai capsaicin in management of overactive bladder and hypersensitive bladder." 09/01/2004 - "PURPOSE: Overactive bladder symptoms due to various etiologies have been successfully treated with capsaicin by desensitization of the temperature sensitive vanilloid receptor TRPV1" 09/01/2003 - "The evaluation process required approximately 14 (overactive bladder) and 11 (hypersensitive bladder and primary detrusor instability) participants who received capsaicin intravesically" 02/01/2000 - "We present the background and basic and clinical research dealing with intravesical instillation of capsaicin and resinfferatoxin as treatments for the overactive bladder" Get all the results and reference details, order at left...
10.	Succinic Acid (Succinate)IBA 11/01/2006 - "Solifenacin succinate is a new once-daily antimuscarinic agent that is an effective and well-tolerated treatment option for patients who have overactive bladder" 03/01/2008 - "Is solifenacin succinate safe and effective for the treatment of overactive bladder?" 01/01/2007 - "A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder]" 01/01/2005 - "OBJECTIVE: To assess the effect of solifenacin succinate treatment on quality of life (QoL) measured in clinical trials in patients with overactive bladder (OAB)" 11/01/2004 - "Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder." Get all the results and reference details, order at left...
160 Drugs and Important Bio-Agents and 581 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2006 - "BACKGROUND: The efficacy of antimuscarinic drug therapy in patients who have more severe symptoms of overactive bladder (OAB) at baseline has not been evaluated thoroughly" 11/01/2006 - "Pharmacotherapy is the first-line treatment for overactive bladder, but many patients discontinue drug therapy because of intolerable side effects, expense, or lack of longterm adherence" 09/01/2008 - "Drug therapy for overactive bladder (OAB) is associated with improvements in symptoms and quality of life, but the short- and long-term adherence and persistence is suboptimal" 09/01/2008 - "A review of adherence to drug therapy in patients with overactive bladder." 04/01/2008 - "BACKGROUND: Pharmacotherapy constitutes an important adjunct to behavioral therapy for the treatment of overactive bladder (OAB)" Get all the results and reference details, order at left...
2.	Biofeedback (Psychology) (Biofeedback) 01/01/2004 - "OBJECTIVES: To compare the efficacy of pelvic floor muscle training (PFMT), biofeedback-assisted PFMT (BAPFMT), and electrical stimulation (ES) in the management of overactive bladder (OAB)" 03/01/2005 - "Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder." 01/01/2004 - "Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder." 11/01/2000 - "During biofeedback training patients were instructed to contract the anal sphincter without raising abdominal pressure to inhibit overactive bladder contractions" 05/01/2000 - "Biofeedback in overactive bladder." Get all the results and reference details, order at left...
3.	Transcutaneous Electric Nerve Stimulation (TENS) 11/01/2007 - "METHODS: We reviewed the data of 18 children (13 girls and 5 boys; mean age 9 years) with overactive bladder refractory to standard therapy who underwent at-home TENS treatment twice daily for 20 minutes" 11/01/2007 - "OBJECTIVES: To examine the outcome of transcutaneous electrical nerve stimulation (TENS) use in children with overactive bladder refractory to behavioral and anticholinergic therapy" 11/01/2007 - "Efficacy of transcutaneous electrical nerve stimulation in children with overactive bladder refractory to pharmacotherapy." Get all the results and reference details, order at left...
4.	Denervation 05/01/2000 - "In conclusion, although in approximately 90% of patients the symptoms of an overactive bladder will be eliminated or improved by conservative methods of treatment, bladder denervation procedures still have a place in the management of these patients" Get all the results and reference details, order at left...
5.	Suburethral Slings (Tension-Free Vaginal Tape) 06/01/2007 - "OBJECTIVE: To determine whether preoperative pressure-flow studies (PFS) predict the resolution of detrusor overactivity (DO) and overactive bladder (OAB) symptoms after a tension-free vaginal tape procedure (TVT)" 06/01/2007 - "The predictive value of preoperative pressure-flow studies in the resolution of detrusor overactivity and overactive bladder after tension-free vaginal tape insertion." 01/01/2008 - "However, patients should be fully advised of the possibility of persistent overactive bladder symptoms and treatment for those symptoms after tension-free vaginal tape should be considered." 06/16/2007 - "The first woman was treated with transobturator tape due to stress incontinence and an overactive bladder" 12/01/2004 - "Prevalence of persistent and de novo overactive bladder symptoms after the tension-free vaginal tape." Get all the results and reference details, order at left...
34 Therapies and Procedures and 88 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Overactive Urinary Bladder

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 112 Outcomes
Top 160 Key Medications
Top 34 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>